Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams

It gives you pharmacist specific information regarding to chemotherapies instead of all the clinical information. Fit my purpose.

I would call it a handbook--very concise (169 pages). Not too in depth, however, there is a brief diagram for each class on the mechanism of action and clinical nuggets for each drug class. Good as an overview or reference. For more in depth information, consider an alternative book.

This is a great review source. I am a heme/onc fellow, and I used this book as a part of my oncology boards review prep.

It looks like 6 inches of the pages are missing on every single page. The cover, the back, and the spine of the book look normal on the outside, but as soon as you open the book, it has nothing to do with oncology. It’s seems as though the book “the psychology of oppression” was printed in place of cancer pharmacology. Seriously at a loss for how this happened.

Perfect

Not what I was looking for. The book is too sparse ... probably good for a pharmacology or biochemist guru

The book handles practically all major anti-cancer medicines classes from conventional chemoterapy to novel targeted therapies. It is divided into main classes with most representative medicines for each and brief explanation of the class mechanism of action. It can be used in clinical rounds by oncologists or onco pharmacists as it has bedside clinical useful information for each class/specific meds such as common dosing ranges, drug interactions, adverse events. It provides indication (type of cancer for medicine to be used) but not clear if drug/class is 1st line, to be used in combination, etc. That and in terms of appeal of information is where the book falls short. Format is consistent but too dense and repetitive for anything major (e.g. black box type of info) to really stand out. As examples of classes/specific medicines I liked chapter 3 on enzyme inhibitors - Topoisomerase I inhibitors - camptothecans - example of specific med Irinotecan where it explains its indication is metastatic colorectal cancer and that mechanism of action is because drug binds to Topoisomerase I thus impeding its proper enzymatic function of relieving DNA tension and supercoiling. Hence inhibition results in no religation of DNA. The chapter doesn't mention nuances and specificities such as Irinotecan liposome injection in combination with fluoracil and leucovirin for the treatment of metastatic adenocarcinoma of the pancreas after after disease progression following gemcitabine-based therapy. Another example of class/specific med is chapter 8 on tyrosine kinase inhibitors /cabozantinib for thyroid cancer, with mechanism of action arising from inhibition of tyrosine kinase normal binding to vascular endothelial factor (VEGF) and so no angiogenesis necessary for tumor. Moreover it also targets MET. You can quickly find information such as this regarding the medicine you want to prescribe, apply or advise the patient about.